- Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic markerRajan Dewar
Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston MA, USA
Cancer Biol Ther 11:552-8. 2011..Additionally, proteasomal inhibition by bortezomib may be a promising therapeutic option in Philadelphia-positive ALL, where FoxO3 is downregulated...
- Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathologyRajan Dewar
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
Arch Pathol Lab Med 135:422-9. 2011....
- Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cellsOctavian Bucur
Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America Institute of Biochemistry of the Romanian Academy, Bucharest, Romania
PLoS ONE 8:e77390. 2013..These results open novel possibilities for the treatment of Bcr-Abl-positive leukemias, especially in the imatinib, dasatinib and nilotinib-resistant CML cases. ..